Skip directly to content

Improving Patient Care in Anticoagulation (IPCA)

People with Atrial Fibrillation (AF) are five times more likely to have a stroke than people unaffected by the condition and AF is a contributing factor to 20% of all strokes in the UK.1 Appropriate treatment with anticoagulation reduces the risk of stroke.2 NICE CG180 recommend all patients with AF and a CHA2DS2-VASc score of 2 or above should receive oral anticoagulation, taking bleeding risk into account.2

The IPCA programme will focus on the priority objectives for the management of patients with AF as identified by the Academic Health Science Networks (AHSN) – detect, protect and perfect.3

  • Detecting individuals with AF so that all those who need it have access to preventative care
  • Protecting patients by ensuring that all eligible patients have access to treatment with an anticoagulant
  • Perfecting treatment approaches, to ensure optimal treatment for everyone with AF who is receiving an anticoagulant

The programme will be in the form of a service delivered by a third party supplier, Oberoi Consulting and will provide Stroke Prevention in Atrial Fibrillation Audit and Case Finding Service to the selected healthcare organisations. Further information regarding Oberoi Consulting and their Stroke Prevention in Atrial Fibrillation Programme is available here.

Time and availability of resources appear to be barriers to the identification and management of patients with AF. To address this issue, we will also provide practice support overtime funding where required.

Please click here to review further information regarding eligibility and scope of the medical education goods and service grant application

 

How to apply

BMS-Pfizer Alliance invite applications for Stroke Prevention in Atrial Fibrillation (SPAF) and Case Finding Service with or without practice overtime funding.

Click here to apply for IPCA - BMS-Pfizer Alliance Medical Education Goods and Services

Applications will be open from the 1st July 2019. Grants will be assessed and awarded on a first come, first served basis subject to availability and any stated criteria. Proposals will be reviewed by appropriate BMS-Pfizer colleagues.

Maximum funding available is dependent on the size and type of your healthcare organisation.

 

References

  1. Stroke Association. Available at www.stroke.org.uk/professionals/atrial-fibrillation-information-and-resources; Accessed May 2019
  2. NICE CG180. AF: management. 2014. http://www.nice.org.uk/Guidance/CG180; Accessed May 2019
  3. London Clinical Networks. AF Toolkit: Detect, Protect and Perfect. Available at http://www.londonscn.nhs.uk/wp-content/uploads/2017/06/detect-protect-perfect-london-af-toolkit-062017.pdf. Accessed May 2018.

 

PP-GIP-GBR-4391 / May 2019